News
MRK-WI
73.00
0.00%
0.00
BUZZ-Wedbush lifts Revolution Medicines PT as Merck takeover talks heat up
Reuters · 5h ago
BUZZ-U.S. STOCKS ON THE MOVE-Vistra, General Motors, Alphabet
Reuters · 6h ago
BUZZ-Revolution climbs after report of Merck's up to $32 bln buyout talks
Reuters · 6h ago
Deals of the day-Mergers and acquisitions
Reuters · 7h ago
BUZZ-Revolution Medicines gains after report co in talks to be acquired by Merck
Reuters · 20h ago
MERCK & CO- CLEAR, EVIDENCE-BASED RECOMMENDATIONS NEEDED TO ENSURE CHILDREN & ADOLESCENTS RECEIVE RELIABLE PROTECTION AGAINST PREVENTABLE DISEASES
Reuters · 20h ago
MERCK & CO- AS HHS MAKES CHANGES TO THE IMMUNIZATION SCHEDULE, IT IS CRITICAL THAT CHANGES ARE INFORMED BY COMPREHENSIVE DATA
Reuters · 20h ago
PRICE TAG OF $28BN TO $32BN WAS BEING DISCUSSED AS PART OF MERCK-REVOLUTION MEDICINES DEAL - FT
Reuters · 20h ago
Merck in talks to buy biotech Revolution Medicines, Financial Times reports
Reuters · 21h ago
RPT- MERCK IN TALKS TO BUY CANCER DRUGMAKER REVOLUTION MEDICINES-FT
Reuters · 21h ago
SPIE Extends Multi-Technical Maintenance Contract with Merck for Molsheim Site
Reuters · 1d ago
MERCK & CO INC <MRK.N>: JEFFERIES CUTS TARGET PRICE TO $130 FROM $139
Reuters · 2d ago
MERCK & CO INC <MRK.N>: UBS RAISES TARGET PRICE TO $130 FROM $105
Reuters · 2d ago
VAXXAS APPOINTS FORMER MERCK GLOBAL VACCINES PRESIDENT DAVID PEACOCK AS CEO
Reuters · 2d ago
Merck Launches Phase 3 Trial of Calderasib and KEYTRUDA QLEX for KRAS G12C-Mutant Lung Cancer
Reuters · 2d ago
MERCK INITIATES PHASE 3 KANDLELIT-007 TRIAL EVALUATING CALDERASIB (MK-1084), AN INVESTIGATIONAL ORAL KRAS G12C INHIBITOR, IN COMBINATION WITH KEYTRUDA QLEX™ (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH) IN CERTAIN PATIENTS WITH ADVANCED NSCLC
Reuters · 2d ago
Merck Completes Acquisition of Cidara Therapeutics
Reuters · 2d ago
MERCK TO COMPLETE ACQUISITION OF CIDARA THERAPEUTICS
Reuters · 2d ago
Merck & Co. Inc. to Hold Sales and Earnings Conference Call
Reuters · 2d ago
U.S. RESEARCH ROUNDUP-Alphabet, Hershey, Micron Technology
Reuters · 2d ago
More
Webull provides a variety of real-time MRK-WI stock news. You can receive the latest news about MERCK & CO through multiple platforms. This information may help you make smarter investment decisions.
About MRK-WI
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.